Literature DB >> 95661

Study of ansamycin inhibition of a ribonucleic acid-directed deoxyribonucleic acid polymerase by an immobilized template assay.

B I Milavetz, J S Horoszewicz, K L Rinehart, W A Carter.   

Abstract

A series of structurally related ansamycins have been analyzed, in a new immobilized template assay, to determine the mechanism by which they inhibit a ribonucleic acid-directed deoxyribonucleic acid (DNA) polymerase from Moloney murine leukemia virus. By this assay, we can better correlate specific structures of these drugs with inhibitory mechanisms. Using an immobilized template, we were also able to observe drug effects on the stability of complexes formed between the polymerase, a template (polyadenylic acid-agarose), and a primer, as well as to monitor the synthesis of DNA in the presence of drug. For each drug, we determined the complex (intermediate in DNA synthesis) which was primarily affected and whether the effect was due to a destabilization process. Although the activity and specificity of the unsubstituted ansamycins (streptovaricins and rifamycin SV) were modulated by conformation of the molecule and electron density of the aromatic ring, the principal mode of inhibition is, apparently, drug binding to a polymerase-template complex; the drug binds in a manner which prevents subsequent formation of a polymerase-template-primer complex. However, some derivatives of rifamycin SV, when substituted at carbon-3 with bulky or hydrophobic side chains, displayed markedly different modes of action. For example, demethyl dimethyl rifampin prevented the formation of polymerase-template complexes, whereas rifazacyclo 16 acted by promoting the dissociation of polymerase-template-primer complexes.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 95661      PMCID: PMC352260          DOI: 10.1128/AAC.13.3.435

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  The steady state kinetic parameters and non-processivity of Escherichia coli deoxyribonucleic acid polymerase I.

Authors:  W R McClure; T M Jovin
Journal:  J Biol Chem       Date:  1975-06-10       Impact factor: 5.157

2.  Relative biological activities of individual streptovaricins and streptovaricin acetates.

Authors:  K L Rinehart; F J Antosz; K Sasaki; P K Martin; M L Maheshwari; F Reusser; L H Li; D Moran; P F Wiley
Journal:  Biochemistry       Date:  1974-02-26       Impact factor: 3.162

3.  Interaction between murine type-C virus RNA-directed DNA polymerases and rifamycin derivatives.

Authors:  A M Wu; R C Gallo
Journal:  Biochim Biophys Acta       Date:  1974-04-10

4.  Inhibition of three nucleotide polymerases by rifamycin derivatives.

Authors:  F M Thompson; A N Tischler; J Adams; M Calvin
Journal:  Proc Natl Acad Sci U S A       Date:  1974-01       Impact factor: 11.205

5.  Rifamycin derivatives: specific inhibitors of nucleic acid polymerases.

Authors:  G F Gerard; C Gurgo; D P Grandgenett; M Green
Journal:  Biochem Biophys Res Commun       Date:  1973-07-02       Impact factor: 3.575

6.  Rifamycin derivatives strongly inhibiting RNA leads to DNA polymerase (reverse transcriptase) of murine sarcoma viruses.

Authors:  C Gurgo; R Ray; M Green
Journal:  J Natl Cancer Inst       Date:  1972-07       Impact factor: 13.506

7.  Active center of DNA polymerase.

Authors:  A Kornberg
Journal:  Science       Date:  1969-03-28       Impact factor: 47.728

8.  Hydrophobic interaction of human, mouse, and rabbit interferons with immobilized hydrocarbons.

Authors:  M W Davey; E Sulkowski; W A Carter
Journal:  J Biol Chem       Date:  1976-12-10       Impact factor: 5.157

9.  Interaction of human interferons with immobilized hydrophobic amino acids and dipeptides.

Authors:  E Sulkowski; M W Davey; W A Carter
Journal:  J Biol Chem       Date:  1976-09-10       Impact factor: 5.157

10.  RNA-directed DNA polymerase and virus-induced leukemia in mice.

Authors:  A M Wu; R C Ting; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1973-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.